Nose-to-Brain Research Of Oxytocin In Autism Spectrum Disorders
Thursday, November 8, 2012 - 15:20
in Health & Medicine
OptiNose US Inc. has announced that its Norwegian affiliate was awarded $2.1 million by the Research Council of Norway to study its nasal drug delivery technology in the treatment of autism spectrum disorders (ASDs). OptiNose will use this research grant to investigate "nose-to-brain" transport of oxytocin via the patented OptiNose Bi-Directional delivery technology for the treatment of ASDs. Partners who have agreed to collaborate with OptiNose in the project include the Department of Psychiatry at Oslo University Hospital, SINTEF and Smerud Medical Research and Norwegian academic insitutions. read more